日韩精品久久一区二区三区_亚洲色图p_亚洲综合在线最大成人_国产中出在线观看_日韩免费_亚洲综合在线一区

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Industries

Total value of medical imports decreases

By Liu Zhihua | China Daily | Updated: 2019-04-16 09:22
Share
Share - WeChat
Bayer Group's booth at the China International Import Expo in Shanghai on Nov 6, 2018. [Photo/China News Service]

Domestic demand remains robust while prices drop due to intensified competition among pharmaceutical firms

The value of medical and healthcare products China imported last year decreased for the first time in "many years" to about $50.43 billion, down by 9.75 percent year-on-year, according to a report released by the China Chamber of Commerce for Import and Export of Medicine and Health Products.

Business insiders said the cause of the decrease is mainly the lower average price of imported medicine due to intensified competition among pharmaceutical companies, rather than changes in import volume.

They also predicted prices are likely to continue to fall in the next few years, while demand will remain robust, and thus the value of medical and healthcare imports will likely be stable or increase slightly in the future.

According to the report released last month, the import volume of medical and healthcare products increased 9.52 percent year-on-year last year, while the average import price dropped by 17.6 percent year-on-year, resulting in a lower total import value.

Among the imports last year, the decrease in value of Western medicine is the main cause of the total import value decline, especially as the import value of Western medicine and biochemical medicine decreased sharply, the report said.

The value of Western medicine, which often takes up the largest value and volume shares among all medical and healthcare products China imports, plunged 24.05 percent year-on-year in 2018 to about $13.03 billion.

The biochemical medicine import value decreased even more sharply to around $4.75 billion, down by 41.21 percent.

"China's demand for imported medical and healthcare products has remained steady in recent years with a tendency toward growth," said Wang Maochun, vice-president of the chamber. "The decline in import value was mainly due to the price drop rather than a volume decrease."

The volume of Western medicine China imported last year increased 1.75 percent year-on-year, while the volume of biochemical medicine dwindled 7.67 percent compared to that in 2017, according to the report.

Wang said the measures the Chinese government has adopted to increase the affordability and accessibility of medicine, such as the pilot drug group-buying program and the generic drug evaluation method, have intensified competition among pharmaceutical companies, which eventually helps cut prices.

In 2018, the prices of 17 titles of anti-cancer drugs were significantly lowered after they made it into the national reimbursement drug list.

The report said the average price of imported Western medicine formulations fell 25.36 percent year-on-year in 2018, and the average price of biochemical medicines slumped 36.32 percent compared to the previous year.

Wang predicted imported medicine prices will likely continue to decline or remain at current levels in the future.

If the multinational pharmaceutical companies, especially overseas firms that produce original drugs, want to maintain their market share in China - the world's second-largest pharmaceutical market after the United States - their medicine prices must remain at a relatively low level, he said.

Shi Lichen, founder of medical consultancy Beijing Dingchen Consultancy, also predicted that imported medicine prices will likely continue dropping "over a long period".

"China has huge market potential for imported medicine, and the demand is growing fast for generic drugs, but pharmaceutical market competition is becoming increasingly fierce," he said.

That is because Chinese pharmaceutical companies have been building up their research and development capacity over the years, and their product competence is growing, and also because China is reviewing and approving drugs faster so there will be more competitors both from China and abroad, he explained.

Shi said competition in the generic drugs segment will be intense, considering the reimbursement provided by medical insurance programs in China for generic drugs is much more generous than in other countries, such as the US.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 免费黄网站在线播放 | 久久中文字幕一区二区三区 | 国产精品久久久久久久四虎电影 | 欧美成人手机在线 | 国产酒店视频 | 欧美午夜一区二区三区免费大片 | 欧美在线一区二区三区 | 99热在这里只有精品 | 婷婷成人综合 | 91短视频app下载安装无限看丝瓜山东座 | 亚洲一区二区三区在线免费观看 | 日日夜夜天天久久 | 精品不卡| 人人欧美| 色多多成视频人在线观看 | 亚洲自拍偷拍在线 | 欧美日本另类xxx乱大交 | 国产在线观看一区二区三区 | 国产精品福利片免费看 | 天堂va在线 | 三级毛片黄色 | 国产乱偷国产偷高清 | 亚洲一区二区三区免费在线观看 | 精品久久久久久久中文字幕 | 成年免费大片黄在线观看岛国 | 亚洲伦理在线 | 久草福利资源网站免费 | 91短视频app下载安装无限看丝瓜山东座 | 国产一区二区三区免费 | 91在线播放免费不卡无毒 | 成人黄色网战 | 日本不卡视频在线观看 | 国产高清一区二区 | 亚洲AV无码色情第一综合网 | 看片国产| 一个人看aaaa免费中文 | 亚洲精品福利在线 | 精品一二区 | 爽爽影院在线看 | 天天爆操 | 久久精品美女 |